In summary, our data suggest that modifying the adenoviral fiber knob to target CD46 gave rise to a highly effective way to target bladder cancer cells in vitro and in vivo, representing a promising therapeutic approach to treat bladder cancers. The gene discussed is CD46; the disease is urinary bladder carcinoma.